PBL assay specializes in the development of IFN related research Tools. One of their most appreciated assay kit by the IFN research community is the ELISA test kit for all Human IFN Alpha subtypes (41115).

Its unique features such as high sensitivity, matrix compatibility and broad detection of IFN alpha subtypes explain this popularity.

RayBiotech has just announced the release of a new ELISA test technology breakthrough that I am quite thrilled to share with you. If you have precious samples with low abundant target and which require high sensitivity, then this post will be of interest to you!

The RayBio® Immuno-Quantitative ELISA (IQELISA) kit is an innovative assay platform that combines the specificity and ease of use of a sandwich ELISA test with the sensitivity of real-time PCR. This results in an assay that is cutting edge and yet familiar, enabling the use of only 1/10th of the typical sample volume while providing up to 10x more sensitivity than a traditional ELISA test. The IQELISA technology is completely novel, patent pending, and has no equivalent in the market at this time.

Mass spectrometry is a technology which is widely used in most scientific disciplines that require accurate and precise measurement of elemental and molecular components. Its use in the pharmaceutical sector is often associated with the Drug Discovery and Development process. The primordial step to analyze a sample is to perform a sample treatment to enable its study. It really requires know-how to obtain good quality results. The following tips and tricks can help you to rapidly select a protein purification strategy and to anticipate some possible problems.

TIGIT:CD155/CD112 immune inhibition (in green)

Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer treatment most of the Immunotherapeutic successes, are molecules developed to modulate and restore immune response by targeting critical Immune Checkpoints.

Some of them can activate T Cells, and on the opposite, some can inhibit this response against cancer cells, such as PD-1 and CTLA4, two of the most studied Immune Checkpoints. The majority of the popular molecules approved in Immunotherapy which have led to clinical benefits, are antibodies inhibiting immune checkpoint activities, such for PD1 with nivolumab and pembrolizumab, or CTLA4 with ipilumab.